Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines
Authors:
Preprint
Abstract
Summary: Current COVID-19 vaccines are largely limited in their ability to induce broad, durable immunity against emerging viral variants. Design and development of improved vaccines utilizing existing platforms requires an in-depth understanding of the antigenic and immunogenic properties of available vaccines. Here we examined the antigenicity of two of the original COVID-19 vaccines, mRNA-1273 and NVX-CoV2373, by electron microscopy-based polyclonal epitope mapping (EMPEM) of serum from immunized non-human primates (NHPs) and clinical trial donors. Both vaccines induce diverse polyclonal antibody (pAb) responses to the N-terminal domain (NTD) in addition to the receptor-binding domain (RBD) of the Spike protein, with the NTD supersite being an immunodominant epitope. High-resolution cryo-EMPEM studies revealed extensive pAb responses to and around the supersite with unique angles of approach and engagement. NTD supersite pAbs were also the most susceptible to variant mutations compared to other specificities, indicating that ongoing Spike ectodomain-based vaccine design strategies should consider immuno-masking this site to prevent induction of these strain-specific responses.Keywords
All Related Versions
- Published version: Cell Reports, 44 (7), 115986.
This publication has 88 references indexed in Scilit:
- Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2Cell, 2022
- In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodiesCell, 2021
- An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodiesCell, 2021
- N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2Cell, 2021
- Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinCell, 2021
- Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodiesBiochemical and Biophysical Research Communications, 2021
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCell, 2020
- Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of AntibodiesCell, 2020
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike GlycoproteinCell, 2020
- CHARMM‐GUI: A web‐based graphical user interface for CHARMMJournal of Computational Chemistry, 2008